Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Appendiceal GCAs (previously Goblet Cell Carcinoids) are composed of cells with secretory phenotypes. Several grading systems to predict behaviour are available (e.g.Tang). The latest WHO 5th edition adopted a grading system similar to colon adenocarcinomas.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Barriuso J, Nonaka D, Nagaraju R, Shenjere P, Lamarca A,
Keywords: goblet cell adenocarcinomas, tang, who grade,
Introduction: Vascular adhesion protein-1 (VAP-1) is a novel driver of tissue inflammation and fibrosis.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Shah T, Sagar V, Neil D, Liu B, Barriuso J,
Keywords: carcinoid, GEP-NET, VAP-1, ECM, tumour stroma, biomarker,
Introduction: Appendiceal GCAs (previously Goblet Cell Carcinoids) have variable behaviour. Systemic chemotherapy (Chemo) is often extrapolated from colon cancer. KRAS mutations (KRAS-mut) are rare and more often present in Tang-C/high grade. The role of anti-EGFR antibodies (MoAb) is unknown.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Barriuso J, Martin A, Chakrabarty B, Burghel G, Lamarca A,
Keywords: goblet cell adenocarcinomas, chemotherapy, anti-egfr,
Introduction: Progression-free survival (PFS) has been used as surrogate endpoint in phase III trials with somatostatin analogues for gastroentero-pancreatic neuroendocrine tumors (GEP-NET). However, this endpoint has not been validated in this scenario.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Jimenez Fonseca P
Authors: Jimenez-Fonseca P, Carmona-Bayonas A, Lamarca A, Barriuso J, Castaño A,
Keywords: somatostatin analogues, surrogate, PFS, OS, correlation, kendall,
Introduction: Somatostatin analogues (SSA), octreotide LAR (Oct) and lanreotide autogel (Lan), significantly prolong progression-free survival (PFS) in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NET). However, comparative data are not available and randomized trials comparing both SSAs are unlikely to be conducted.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Carmona-Bayonas A, Jimenez-Fonseca P, Lamarca A, Barriuso J, Castaño A,
Keywords: Bayesian model, octreotide, lanreotide, progression-free survival, efficacy,